News
Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...
The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...
The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.
Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...
The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...
Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...
Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.
Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results